- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00081224
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Celecoxib may also make tumor cells more sensitive to chemotherapy and radiation therapy. Giving celecoxib with capecitabine and radiation therapy before surgery may shrink the tumor so that it can be removed.
PURPOSE: This phase II trial is studying how well giving neoadjuvant celecoxib together with capecitabine and pelvic irradiation works in treating patients with stage II or stage III adenocarcinoma (cancer) of the rectum.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- Determine the pathological complete response rate in patients with stage II or III adenocarcinoma of the rectum treated with neoadjuvant celecoxib and capecitabine in combination with pelvic irradiation.
Secondary
- Determine the safety and tolerability of this regimen in these patients.
- Determine the rectal function of patients treated with this regimen.
- Determine the time to recurrence or progression and survival time of patients treated with this regimen.
- Correlate cellular and molecular markers in pretreatment tumor samples with response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.
- Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.
- Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed rectal adenocarcinoma
- Clinical stage T3, N0, M0 OR any T, N1-3, M0 disease
Treatment with neoadjuvant chemotherapy and pelvic radiotherapy is indicated
- All disease must be encompassable within standard pelvic radiotherapy fields
- Distal border of the tumor must be at or below* the peritoneal reflection, defined as within 12 cm of the anal verge by endoscopy NOTE: *If a portion of the tumor is below the peritoneal reflection at the time of surgery, patients are eligible regardless of the distance of the tumor determined at endoscopy
Tumor must be determined to be clinically resectable
- Tumor may not be clinically fixed
- Negative margins by routine examination of an unanesthetized patient
- Transmural penetration of tumor through the muscularis propria by CT scan, endorectal ultrasound, or MRI
No distant metastatic disease
No evidence of tumor outside the pelvis, including any of the following:
- Metastatic inguinal lymphadenopathy
- Peritoneal seeding
- Liver metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- At least 6 months
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ upper limit of normal (ULN)
- AST ≤ 3 times ULN
- Alkaline phosphatase ≤ 4 times ULN if AST < ULN
Renal
- Creatinine clearance ≥ 30 mL/min
- No renal impairment
Cardiovascular
- No congestive heart failure
- No symptomatic coronary artery disease
- No uncontrolled cardiac arrhythmias
- No myocardial infarction
- No history of transient ischemic attacks or stroke
- No other clinically significant cardiac disease
Gastrointestinal
- No bleeding peptic ulcer disease within the past 12 months
- No lack of physical integrity of the upper gastrointestinal tract
- No malabsorption syndrome
- No active inflammatory bowel disease
- Must be able to swallow study drugs
Other
- No dihydropyrimidine dehydrogenase deficiency
- No history of uncontrolled seizures
- No CNS disorders
- No clinically significant psychiatric illness that would preclude study compliance or giving informed consent
- No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No known sensitivity to NSAIDs, sulfonamides, or aspirin
- No other serious medical illness that would preclude study treatment
- No other conditions that would preclude study participation
- Must be able to tolerate major surgery that may include abdominal-perineal resection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
- No prior systemic anticancer chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- No prior radiotherapy to the pelvis
Surgery
- See Disease Characteristics
- More than 3 weeks since prior major surgery and recovered
Other
- At least 7 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin
- No other concurrent investigational drugs
- No other concurrent anticancer treatment
- No concurrent NSAIDs
- No concurrent primary prophylactic therapy for hand-foot syndrome
- No concurrent loperamide prophylaxis for diarrhea
- No concurrent sorivudine or brivudine
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: celecoxib + capecitabine + radiation + surgery
Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks. Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy. Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Proportion of successes
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Tiempo de supervivencia
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
Supervivencia
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
Time-to event analyses
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Time to disease progression/recurrence
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Time to recurrence
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Time to first progression
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Bowel function as measured by the Patient Bowel Function (Uniscale) Questionnaire, the FACT Diarrhea Subscale and the Mayo Bowel Function Questionnaire
Periodo de tiempo: Up to 5 years
|
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Frank Sinicrope, MD, Mayo Clinic
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes del sistema nervioso periférico
- Inhibidores de enzimas
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Inhibidores de la ciclooxigenasa
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Inhibidores de la ciclooxigenasa 2
- Capecitabina
- Celecoxib
Otros números de identificación del estudio
- NCCTG-N0346
- NCI-2012-02582 (Identificador de registro: CTRP (Clinical Trials Reporting System))
- CDR0000360666 (Identificador de registro: PDQ (Physician Data Query))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer colonrectal
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre cirugía
-
Seattle Children's HospitalJohns Hopkins University; Duke University; Vanderbilt University; University of Utah y otros colaboradoresReclutamientoEscoliosis idiopática | Espondilolistesis | Escoliosis; Adolescencia | Cifosis | Juvenil; Escoliosis | Escoliosis; CongénitaEstados Unidos
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... y otros colaboradoresTerminadoCáncer de ovarios | Cáncer de trompa de Falopio | Cáncer de cavidad peritonealEspaña, Francia, Dinamarca, Bélgica, Alemania, Austria, Porcelana, Italia, Corea, república de, Noruega, Suecia, Reino Unido
-
Kocaeli Derince Education and Research HospitalKocaeli UniversityDesconocidoRecuperación mejorada después de la cirugía | Cirugía a corazón abiertoPavo
-
University of TriesteTerminado
-
Dr. Faruk SemizInscripción por invitación
-
National Cancer Centre, SingaporeTerminadoEnfermedades de la tiroidesSingapur
-
Ethicon Endo-SurgeryTerminadoObesidadEstados Unidos, Alemania
-
University of Illinois at ChicagoEthicon Endo-SurgeryRetiradoEnfermedades del colon y del rectoEstados Unidos
-
St. Joseph's Healthcare HamiltonHamilton Academic Health Sciences OrganizationTerminadoCáncer de pulmón de células no pequeñasCanadá
-
Assistance Publique - Hôpitaux de ParisDesconocidoCirugía | Artroplastia total de rodilla | Colectomía | HisterectomíaFrancia